Charles Schwab Investment Management Inc Fate Therapeutics Inc Transaction History

Charles Schwab Investment Management Inc

$515 Billion
Q3 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 763,808 shares of FATE stock, worth $1.53 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

763,808

Previous 879,375 13.14%

Holding current value

$1.53 Million

Previous $2.88 Million 7.32%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$3.12 - $5.57 $360,569 - $643,708	-115,567 Reduced 13.14%	763,808 $2.67 Million
Q2 2024 Aug 12, 2024	SELL	$3.26 - $7.08 $250,876 - $544,848	-76,956 Reduced 8.05%	879,375 $2.88 Million
Q1 2024 May 08, 2024	SELL	$3.54 - $8.35 $94,475 - $222,844	-26,688 Reduced 2.71%	956,331 $7.02 Million
Q4 2023 Feb 06, 2024	BUY	$1.65 - $3.94 $158,901 - $379,437	96,304 Added 10.86%	983,019 $3.68 Million
Q3 2023 Nov 08, 2023	BUY	$2.02 - $5.04 $504,862 - $1.26 Million	249,932 Added 39.25%	886,715 $1.88 Million
Q2 2023 Aug 09, 2023	BUY	$4.76 - $6.59 $85,432 - $118,277	17,948 Added 2.9%	636,783 $3.03 Million
Q1 2023 May 11, 2023	BUY	$4.24 - $11.12 $17,816 - $46,726	4,202 Added 0.68%	618,835 $3.53 Million
Q4 2022 Feb 13, 2023	BUY	$9.86 - $23.83 $129,708 - $313,483	13,155 Added 2.19%	614,633 $6.2 Million
Q3 2022 Nov 14, 2022	SELL	$21.04 - $36.06 $4.64 Million - $7.95 Million	-220,505 Reduced 26.83%	601,478 $13.5 Million
Q2 2022 Aug 15, 2022	BUY	$17.78 - $42.39 $117,365 - $279,816	6,601 Added 0.81%	821,983 $20.4 Million
Q1 2022 May 13, 2022	BUY	$29.67 - $60.28 $613,397 - $1.25 Million	20,674 Added 2.6%	815,382 $31.6 Million
Q4 2021 Feb 11, 2022	BUY	$47.84 - $64.34 $831,507 - $1.12 Million	17,381 Added 2.24%	794,708 $46.5 Million
Q3 2021 Nov 16, 2021	BUY	$59.27 - $95.73 $11.5 Million - $18.6 Million	194,189 Added 33.3%	777,327 $46.1 Million
Q2 2021 Aug 16, 2021	BUY	$67.25 - $92.52 $1.26 Million - $1.74 Million	18,796 Added 3.33%	583,138 $50.6 Million
Q1 2021 May 17, 2021	BUY	$72.16 - $117.4 $6.06 Million - $9.85 Million	83,914 Added 17.47%	564,342 $46.5 Million
Q4 2020 Feb 16, 2021	BUY	$38.09 - $100.95 $241,528 - $640,123	6,341 Added 1.34%	480,428 $43.7 Million
Q3 2020 Nov 13, 2020	BUY	$30.41 - $40.5 $906,674 - $1.21 Million	29,815 Added 6.71%	474,087 $19 Million
Q2 2020 Aug 14, 2020	BUY	$20.21 - $35.23 $1.19 Million - $2.07 Million	58,866 Added 15.27%	444,272 $15.2 Million
Q1 2020 May 15, 2020	BUY	$17.28 - $31.88 $89,752 - $165,584	5,194 Added 1.37%	385,406 $8.56 Million
Q4 2019 Feb 07, 2020	BUY	$13.39 - $20.73 $519,572 - $804,386	38,803 Added 11.37%	380,212 $7.44 Million
Q3 2019 Nov 08, 2019	BUY	$15.47 - $22.5 $3.26 Million - $4.74 Million	210,836 Added 161.47%	341,409 $5.3 Million
Q2 2019 Aug 09, 2019	SELL	$15.61 - $20.44 $214,777 - $281,233	-13,759 Reduced 9.53%	130,573 $2.65 Million
Q1 2019 May 14, 2019	BUY	$13.15 - $18.71 $76,191 - $108,405	5,794 Added 4.18%	144,332 $2.54 Million
Q4 2018 Feb 14, 2019	BUY	$11.48 - $16.98 $316,595 - $468,274	27,578 Added 24.85%	138,538 $1.78 Million
Q3 2018 Nov 13, 2018	BUY	$8.75 - $16.29 $49,525 - $92,201	5,660 Added 5.38%	110,960 $1.81 Million
Q2 2018 Aug 08, 2018	BUY	$9.16 - $13.48 $71,448 - $105,144	7,800 Added 8.0%	105,300 $1.2 Million
Q1 2018 May 07, 2018	BUY	$6.3 - $13.77 $198,450 - $433,755	31,500 Added 47.73%	97,500 $952,000
Q3 2017 Nov 13, 2017	BUY	$2.6 - $4.31 $171,600 - $284,460	66,000	66,000 $262,000

Others Institutions Holding FATE

# of Institutions

175

Shares Held

115M

Call Options Held

53.7K

Put Options Held

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $194M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Fate Therapeutics Inc Transaction History